

February 07, 2020

To, The Manager Listing Department, **The National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Product Registration in Cambodia

Ref.: Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that we, Zota Health Care Limited (the "Company") have received product registration license for below mentioned 1 product from Ministry of Health, Cambodia.

Sr.	Name of Product	Therapeutic Category
No.		5
1	Zogab 75 (Cap – Each Capsule contains Pregabalin 75mg)	Anticonvulsants

We have received license for the aforementioned product for the period of five years, licenses for the product is also renewable. Company shall start exporting this product in Cambodia very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya (Company Secretary & Compliance Officer) Place: Surat



Registered Office :

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122